Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of Ad26.COV2.S in healthy pregnant adults
2020-005330-14Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Ad26.COV2.S in coronavirus disease 2019 (COVID-19), sponsored by Janssen Pharmaceutical. Primary endpoints: Solicited local adverse events and Solicited systemic adverse events. Started Oct 2021; status: terminated.
02
Drugs
Ad26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-005330-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005330-14.